A news release posted today by docguide.com:
The US Food and Drug Administration (FDA) today approved paliperidone palmitate (Invega Sustenna) extended-release injectable suspension for the acute and maintenance treatment of schizophrenia in adults. It is the first once-monthly, long-acting, injectable atypical antipsychotic approved in the United States for this use.
Bold emphasis in the text is mine.
To read the entire news release, please click here.
FDA Approves INVEGA® SUSTENNA™ for the Acute and Maintenance Treatment of Schizophrenia
FDA Approves First Monthly Atypical Antipsychotic for Schizophrenia
Monthly Shot Treats Schizophrenia